AMENDMENTS TO THE CLAIMS

Please amend claims 8 and 36, and cancel claims 46-47, as shown.

1-7. (Canceled).

8. (Currently Amended) A composition for affecting weight loss comprising a sustained release formulation of a weight loss affecting amount of a first compound and a second compound, wherein said first compound is naltrexone, or a pharmaceutically acceptable salt or prodrug thereof, and said second compound comprises bupropion, or a pharmaceutically acceptable salt or prodrug thereof, and wherein said bupropion, or a pharmaceutically acceptable salt thereof, is a sustained release formulation.

9. (Previously Presented) The composition of claim 8, wherein said first compound is naltrexone or a pharmaceutically acceptable salt thereof, and said second compound is bupropion or a pharmaceutically acceptable salt thereof.

10. (Withdrawn) A method of affecting weight loss, comprising identifying an individual in need thereof and treating that individual with a composition according to Claim 8.

11. (Withdrawn) The method of claim 10, wherein said individual has a body mass index greater than 25.

12-23. (Canceled).

24. (Withdrawn) The method of claim 10, wherein said individual is not suffering from depression.

25. (Withdrawn) The method of claim 10, wherein said first compound is naltrexone or a pharmaceutically acceptable salt thereof, and said second compound is bupropion or a pharmaceutically acceptable salt thereof.

26. (Withdrawn) A method of increasing satiety in an individual comprising identifying an individual in need thereof and treating that individual with a composition according to Claim 8.

27-28. (Canceled).

29. (Withdrawn) The method of claim 26, wherein said individual is not suffering from depression.

30. (Withdrawn) The method of claim 26, wherein said first compound is naltrexone or a pharmaceutically acceptable salt thereof, and said second compound is bupropion or a pharmaceutically acceptable salt thereof.

31. (Withdrawn) A method of suppressing the appetite of an individual comprising identifying an individual in need thereof and treating that individual with a composition according to Claim 8.

32-33. (Canceled).

34. (Withdrawn) The method of claim 31, wherein said individual is not suffering from depression.

35. (Withdrawn) The method of claim 31, wherein said first compound is naltrexone or a pharmaceutically acceptable salt thereof, and said second compound is bupropion or a pharmaceutically acceptable salt thereof.

36. (Currently Amended) A pharmaceutical composition comprising a sustained release formulation of a weight loss affecting amount of a first compound and a second compound, and a pharmaceutically acceptable excipient, diluent, or carrier, wherein said first compound is naltrexone, or a pharmaceutically acceptable salt or prodrug thereof, and wherein said second compound comprises bupropion, or a pharmaceutically acceptable salt or prodrug thereof, and wherein said bupropion, or a pharmaceutically acceptable salt thereof, is a sustained release formulation.

37. (Previously Presented) The pharmaceutical composition of claim 36, wherein said first compound is naltrexone or a pharmaceutically acceptable salt thereof, and said second compound is bupropion or a pharmaceutically acceptable salt thereof.

38. (Previously Presented) The composition of claim 9, wherein said amount of naltrexone, or a pharmaceutically acceptable salt thereof, is about 5 mg to about 50 mg.

39. (Previously Presented) The composition of claim 9, wherein said amount of bupropion, or a pharmaceutically acceptable salt thereof, is about 30 mg to about 300 mg.

40. (Previously Presented) The composition of claim 9, wherein said amount of naltrexone, or a pharmaceutically acceptable salt thereof, is about 5 mg to about 50 mg, and wherein said amount of bupropion, or a pharmaceutically acceptable salt thereof, is about 30 mg to about 300 mg.

41. (Previously Presented) The pharmaceutical composition of claim 37, wherein said amount of naltrexone, or a pharmaceutically acceptable salt thereof, is about 5 mg to about 50 mg.

42. (Previously Presented) The pharmaceutical composition of claim 37, wherein said amount of bupropion, or a pharmaceutically acceptable salt thereof, is about 30 mg to about 300 mg.

43. (Previously Presented) The pharmaceutical composition of claim 37, wherein said amount of naltrexone, or a pharmaceutically acceptable salt thereof, is about 5 mg to about 50 mg, and wherein said amount of bupropion, or a pharmaceutically acceptable salt thereof, is about 30 mg to about 300 mg.

44. (Previously Presented) The composition of claim 8, wherein the second compound further comprises zonisamide, or a pharmaceutically acceptable salt or prodrug thereof.

45. (Previously Presented) The pharmaceutical composition of claim 36, wherein the second compound further comprises zonisamide, or a pharmaceutically acceptable salt or prodrug thereof.

46-47. (Canceled).

48. (Previously Presented) The pharmaceutical composition of claim 36, wherein said pharmaceutical composition is formulated for oral administration.

49. (Previously Presented) The pharmaceutical composition of claim 36, wherein said pharmaceutical composition is formulated for administration by injection.